

***Amendments to the Claims***

1-76. (cancelled)

77. (withdrawn) An isolated peptide less than 15 amino acids in length  
comprising an oligopeptide selected from the group consisting of:

FLLLADARV (SEQ ID NO:3568)  
YLVAYQATV (SEQ ID NO:3569)  
RLIVFPDLGV (SEQ ID NO:3570)  
ILAGYGAGV (SEQ ID NO:3575)  
YLLPRRGPRV (SEQ ID NO:3576) and  
YLVTRHADV (SEQ ID NO:3578).

78. (withdrawn) The peptide of claim 77, which is 11 amino acids in length.

79. (withdrawn) The peptide of claim 77, which is 10 amino acids in length.

80. (withdrawn) The peptide of claim 77, which is 9 amino acids in length,  
wherein said oligopeptide is selected from the group consisting of:

FLLLADARV (SEQ ID NO:3568)  
YLVAYQATV (SEQ ID NO:3569)  
ILAGYGAGV (SEQ ID NO:3575) and  
YLVTRHADV (SEQ ID NO:3578).

81. (withdrawn) The peptide of claim 77, which is fused to a T helper peptide.

82. (withdrawn) The peptide of claim 77, which is fused to spacer or linker  
amino acids.

83. (withdrawn) The peptide of claim 77, which is fused to a carrier.

84. (withdrawn) The peptide of claim 77, which is linked to a lipid.

85. (withdrawn) A fusion protein comprising the peptide of claim 77.

86. (withdrawn) A homopolymer of the peptide of claim 77.

87. (withdrawn) A heteropolymer of the peptide of claim 77 and a different peptide.
88. (withdrawn) A composition comprising the peptide of claim 77 and a carrier.
89. (withdrawn) A pharmaceutical composition comprising the peptide of claim 77 and a carrier.
90. (withdrawn) A composition comprising the peptide of claim 77 and a liposome.
91. (withdrawn) A vaccine comprising the peptide of claim 77 and a pharmaceutically acceptable carrier.
92. (withdrawn) A composition comprising the peptide of claim 77, and one or more second peptides.
93. (withdrawn) The composition of claim 92, wherein said peptides form a fusion protein.
94. (withdrawn) The composition of claim 92, which comprises a carrier.
95. (withdrawn) A pharmaceutical composition comprising the composition of claim 92 and a carrier.
96. (withdrawn) The composition of claim 92, wherein said peptides are fused by spacer or linker amino acids.
97. (withdrawn) A vaccine comprising the composition of claim 92 and a pharmaceutically acceptable carrier.
- 98-121. (cancelled)
122. (withdrawn) An isolated peptide 9, 10, or 11 amino acids in length comprising the oligopeptide DLMGYIPLV (SEQ ID NO:3571).

123. (withdrawn) The peptide of claim 122, which is 10 amino acids in length.
124. (withdrawn) The peptide of claim 122, which is 9 amino acids in length.
125. (withdrawn) The peptide of claim 122, which is fused to a T helper peptide.
126. (withdrawn) The peptide of claim 122, which is fused to spacer or linker amino acids.
127. (withdrawn) The peptide of claim 122, which is fused to a carrier.
128. (withdrawn) The peptide of claim 122, which is linked to a lipid.
129. (withdrawn) A fusion protein comprising the peptide of claim 122.
130. (withdrawn) A homopolymer of the peptide of claim 122.
131. (withdrawn) A heteropolymer of the peptide of claim 122 and a different peptide.
132. (withdrawn) A composition comprising the peptide of claim 122 and a carrier.
133. (withdrawn) A pharmaceutical composition comprising the peptide of claim 122 and a carrier.
134. (withdrawn) A composition comprising the peptide of claim 122 and a liposome.
135. (withdrawn) A vaccine comprising the peptide of claim 122 and a pharmaceutically acceptable carrier.
136. (withdrawn) A composition comprising the peptide of claim 122, and one or more second peptides.
137. (withdrawn) The composition of claim 136, wherein said peptides form a fusion protein.

138. (withdrawn) The composition of claim 136, which comprises a carrier.
139. (withdrawn) A pharmaceutical composition comprising the composition of claim 136 and a carrier.
140. (withdrawn) The composition of claim 136, wherein said peptides are fused by spacer or linker amino acids.
141. (withdrawn) A vaccine comprising the composition of claim 136 and a pharmaceutically acceptable carrier.

142-165. (cancelled)

166. (currently amended) An isolated peptide ~~less than 15 amino acids in length~~ comprising an oligopeptide less than 15 amino acids in length selected from the group consisting of:

CTCGSSDLY (SEQ ID NO:3591);  
KTSERSQPR (SEQ ID NO:3579);  
QLFTFSPRR (SEQ ID NO:3581);  
RMYVGGVEHR (SEQ ID NO:3582);  
LIFCHSKKK (SEQ ID NO:3583);  
GVAGALVAFK (SEQ ID NO:3584); and  
TLGFGAYMSK (SEQ ID NO:3586).

167. (withdrawn) The peptide of claim 166, which is 11 amino acids in length.
168. (previously presented) The peptide of claim 166, which is 10 amino acids in length.
169. (withdrawn) The peptide of claim 166, which is 9 amino acids in length, wherein said oligopeptide is selected from the group consisting of:

CTCGSSDLY (SEQ ID NO:3591)  
KTSERSQPR (SEQ ID NO:3579)  
QLFTFSPRR (SEQ ID NO:3581) and  
LIFCHSKKK (SEQ ID NO:3583).

170. (currently amended) The isolated peptide of claim 166, ~~which is fused to~~  
further comprising a T helper peptide linked to said isolated peptide.
171. (withdrawn) The peptide of claim 166, which is fused to spacer or linker amino acids.
172. (withdrawn) The peptide of claim 166, which is fused to a carrier.
173. (withdrawn) The peptide of claim 166, wherein said peptides are fused by spacer or linker amino acids.
174. (withdrawn) A fusion protein comprising the peptide of claim 166.
175. (withdrawn) A homopolymer of the peptide of claim 166.
176. (withdrawn) A heteropolymer of the peptide of claim 166 and a different peptide.
177. (previously presented) A composition comprising the peptide of claim 166 and a carrier.
178. (cancelled)
179. (withdrawn) A composition comprising the peptide of claim 166 and a liposome.
180. (cancelled)
181. (withdrawn) A composition comprising the peptide of claim 166, and one or more second peptides.
182. (withdrawn) The composition of claim 181, wherein said peptides form a fusion protein.
183. (withdrawn) The composition of claim 181, which comprises a carrier.

- 184. (withdrawn) A pharmaceutical composition comprising the composition of claim 181 and a carrier.
- 185. (withdrawn) The composition of claim 181, wherein said peptides are fused by spacer or linker amino acids.
- 186. (withdrawn) A vaccine comprising the composition of claim 181 and a pharmaceutically acceptable carrier.
- 187-204. (cancelled)
- 205. (withdrawn) A method of inducing a cytotoxic T cell (CTL) response against hepatitis C virus (HCV) in a human in need of treatment or prevention of HCV infection, comprising administering a composition comprising a peptide of claim 77 to said human.
- 206. (withdrawn) The method of claim 205, wherein said peptide is fused to a T helper peptide.
- 207. (withdrawn) The method of claim 205, wherein said peptide is fused to spacer or linker amino acids.
- 208. (withdrawn) The method of claim 205, wherein said peptide is fused to a carrier.
- 209. (withdrawn) The method of claim 205, wherein said peptide is linked to a lipid.
- 210. (withdrawn) The method of claim 205, wherein said composition comprises a liposome.
- 211. (withdrawn) The method of claim 205, wherein said composition comprises a pharmaceutically acceptable carrier.

- 212. (withdrawn) The method of claim 205, wherein said composition comprises one or more second peptides.
- 213. (withdrawn) The method of claim 212, wherein said peptides form a fusion protein.
- 214. (withdrawn) A method for diagnosing or prognosing HCV infection in a human comprising detecting a CTL response of said human against a peptide of claim 77.
- 215. (withdrawn) The method of claim 214, wherein said response is detected by direct cytotoxicity.
- 216. (withdrawn) The method of claim 214, wherein said response is detected by an assay selected from the group consisting of: proliferation, lymphokine secretion, limiting dilution, tetramer staining, intracellular lymphokine staining, and ELISPOT.
- 217. (withdrawn) A method of determining susceptibility of a human to a therapy for HCV infection comprising detecting a CTL response of said human against a peptide of claim 77.
- 218. (withdrawn) The method of claim 217, wherein said response is detected by an assay selected from the group consisting of: proliferation, lymphokine secretion, direct cytotoxicity, limiting dilution, tetramer staining, intracellular lymphokine staining, and ELISPOT.
- 219. (withdrawn) A method of inducing a CTL response against HCV in a human in need of treatment or prevention of HCV infection, comprising

administering a composition comprising a peptide of claim 122 to said human.

- 220. (withdrawn) The method of claim 219, wherein said peptide is fused to a T helper peptide.
- 221. (withdrawn) The method of claim 219, wherein said peptide is fused to spacer or linker amino acids.
- 222. (withdrawn) The method of claim 219, wherein said peptide is fused to a carrier.
- 223. (withdrawn) The method of claim 219, wherein said peptide is linked to a lipid.
- 224. (withdrawn) The method of claim 219, wherein said composition comprises a liposome.
- 225. (withdrawn) The method of claim 219, wherein said composition comprises a pharmaceutically acceptable carrier.
- 226. (withdrawn) The method of claim 219, wherein said composition comprises one or more second peptides.
- 227. (withdrawn) The method of claim 226, wherein said peptides form a fusion protein.
- 228. (withdrawn) A method for diagnosing or prognosing HCV infection in a human comprising detecting a CTL response of said human against a peptide of claim 122.
- 229. (withdrawn) The method of claim 228, wherein said response is detected by direct cytotoxicity.



230. (withdrawn) The method of claim 228, wherein said response is detected by an assay selected from the group consisting of: proliferation, lymphokine secretion, limiting dilution, tetramer staining, intracellular lymphokine staining, and ELISPOT.
231. (withdrawn) A method of determining susceptibility of a human to a therapy for HCV infection comprising detecting a CTL response of said human against a peptide of claim 122.
232. (withdrawn) The method of claim 231, wherein said response is detected by an assay selected from the group consisting of: proliferation, lymphokine secretion, direct cytotoxicity, limiting dilution, tetramer staining, intracellular lymphokine staining, and ELISPOT.
233. (withdrawn) A method of inducing a CTL response against HCV in a human in need of treatment or prevention of HCV infection, comprising administering a composition comprising a peptide of claim 166 to said human.
234. (withdrawn) The method of claim 233, wherein said peptide is fused to a T helper peptide.
235. (withdrawn) The method of claim 233, wherein said peptide is fused to spacer or linker amino acids.
236. (withdrawn) The method of claim 233, wherein said peptide is fused to a carrier.
237. (withdrawn) The method of claim 233, wherein said peptide is linked to a lipid.

238. (withdrawn) The method of claim 233, wherein said composition comprises a liposome.
239. (withdrawn) The method of claim 233, wherein said composition comprises a pharmaceutically acceptable carrier.
240. (withdrawn) The method of claim 233, wherein said composition comprises one or more second peptides.
241. (withdrawn) The method of claim 240, wherein said peptides form a fusion protein.
242. (withdrawn) A method for diagnosing or prognosing HCV infection in a human comprising detecting a CTL response of said human against a peptide of claim 166.
243. (withdrawn) The method of claim 242, wherein said response is detected by direct cytotoxicity.
244. (withdrawn) The method of claim 242, wherein said response is detected by an assay selected from the group consisting of: proliferation, lymphokine secretion, limiting dilution, tetramer staining, intracellular lymphokine staining, and ELISPOT.
245. (withdrawn) A method of determining susceptibility of a human to a therapy for HCV infection comprising detecting a CTL response of said human against a peptide of claim 166.
246. (withdrawn) The method of claim 245, wherein said response is detected by an assay selected from the group consisting of: proliferation, lymphokine

secretion, direct cytotoxicity, limiting dilution, tetramer staining, intracellular lymphokine staining, and ELISPOT.